Related Experiment Video
Updated: Sep 16, 2025
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
Molecular diagnostic factors, prognostic implications, and long-term outcomes in pediatric pilocytic astrocytoma
Julia N Grigorian1, Katherine E Chandler1, Vivek A Pisharody1
11Department of Neurosurgery, Emory University School of Medicine.
Insights
Gross-total resection (GTR) improves outcomes for pediatric pilocytic astrocytoma (PPA). KIAA1549-BRAF fusion is linked to worse progression-free survival, but GTR mitigates this risk.
Area of Science:
- Pediatric neuro-oncology
- Cancer genomics
- Brain tumor research
Background:
- Pediatric pilocytic astrocytoma (PPA) is the most common pediatric brain tumor.
- BRAF alterations, including KIAA1549-BRAF (K-B) fusion and BRAF V600E mutation, are common in PA.
- Previous studies show mixed prognostic outcomes for these BRAF alterations.
Purpose of the Study:
- To outline the clinical course of pediatric PPA patients.
- To identify factors predicting disease trajectory in PPA.
- To examine the prognostic impact of BRAF alterations in PPA.
Main Methods:
- Retrospective study of 112 pediatric PPA patients (2009-2023).
- Collected clinical data, tumor genomics, and disease outcomes.
- Analyzed outcomes stratified by BRAF gene status.
Main Results:
- Gross-total resection (GTR) significantly reduced recurrence/progression rates (HR 0.27).
- KIAA1549-BRAF (K-B) fusion associated with worse progression-free survival (PFS) vs. wildtype (WT) (HR 2.3).
- GTR improved PFS for K-B fusion patients (4.5 vs. 0.8 years); BRAF V600E showed no significant PFS difference vs. WT.
Conclusions:
- Clinical and genomic factors impact PPA prognostication.
- K-B fusion is common and linked to worse PFS, but GTR improves outcomes.
- BRAF V600E mutation did not significantly alter PFS compared to WT BRAF.
Objective:
Pediatric pilocytic astrocytoma (PPA) is the most common pediatric brain tumor, accounting for more than 15% of brain tumors in children. BRAF alterations, including KIAA1549-BRAF (K-B) fusion and BRAF V600E mutation, are prevalent in pilocytic astrocytoma (PA) and have shown mixed prognostic outcomes in previous studies. In this study, the authors outline the clinical course for patients with PPA and examine factors that may aid in predicting disease trajectory.
Methods:
This retrospective study included pediatric patients who underwent biopsy or resection of PA between 2009 and 2023 at the authors' institution. Clinical data, tumor genomics, and disease course outcomes were collected, and analysis included stratification by BRAF gene status.
Results:
The study cohort included 112 pediatric patients, 58 of whom had the K-B fusion and 12 of whom had the BRAF V600E mutation. Significantly lower rates of recurrence/progression were noted with gross-total resection (GTR) (hazard ratio [HR] 0.27, 95% CI 0.13-0.53; p < 0.001). The K-B fusion was associated with worse progression-/recurrence-free survival (PRFS) compared to wildtype (WT) (HR 2.3, 95% CI 1.1-4.3; p = 0.03), although among patients with K-B fusion, GTR was associated with a significantly longer time to recurrence/progression (4.5 vs 0.8 years, p < 0.001). The BRAF V600E mutation was not associated with significantly different PRFS than WT (HR 1.4, 95% CI 0.4-4.5; p = 0.56). Neither the use of adjuvant therapy for incompletely resected tumors nor tumor location affected the rate of recurrence/progression.
Conclusions:
Several clinical and genomic factors were identified that may affect prognostication for patients with PPA. K-B was the most common genomic alteration identified and was associated with worse PRFS, while the BRAF V600E mutation conferred no difference in PRFS when compared to the BRAF WT. GTR should be pursued when possible because it is associated with a longer time to recurrence/progression, including for tumors with the K-B fusion.
More Related Videos
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014